

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 October 2024 (31.10.2024)



(10) International Publication Number
WO 2024/224304 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) A61K 9/16 (2006.01)
A61K 31/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2024/053990

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

24 April 2024 (24.04.2024)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/498,398	26 April 2023 (26.04.2023)	US
63/522,996	23 June 2023 (23.06.2023)	US
63/553,453	14 February 2024 (14.02.2024)	US

(71) Applicant: ASSEMBLY BIOSCIENCES, INC.

[US/US]; Two Tower Place, 7th Floor, South San Francisco,
California 94080 (US).

(72) Inventors: ZONG, Zhixin; c/o Assembly Biosciences,

Inc., Two Tower Place, 7th Floor, South San Francisco, California 94080 (US). WHITE, Nicole; c/o Assembly Biosciences, Inc., Two Tower Place, 7th Floor, South San Francisco, California 94080 (US). WU, Yi; c/o Assembly Biosciences, Inc., Two Tower Place, 7th Floor, South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ORAL PHARMACEUTICAL COMPOSITIONS

(57) Abstract: The present invention relates to methods and compositions for treating and/or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection. In particular, provided are oral high bioavailability and long-acting pharmaceutical compositions comprising Compound I; methods for their manufacture; and the use of said pharmaceutical compositions as a medicament and for the treatment of diseases or disorders caused by, or associated with, herpes virus.

WO 2024/224304 A1